Pembrolizumab plus chemotherapy for advanced and recurrent cervical cancer: final analysis according to bevacizumab use in the randomized KEYNOTE-826 study ☆

Overview of attention for article published in Annals of Oncology, October 2024

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (93rd percentile)
High Attention Score compared to outputs of the same age and source (89th percentile)

Mentioned by

news: 1 news outlet
blogs: 1 blog

twitter: 26 X users

Readers on

mendeley: 50 Mendeley

So far, Altmetric has seen 1 blog post.

Adding pembrolizumab to chemotherapy results in improved progression-free survival and overall survival in patients with advanced and recurrent cervical cancer regardless of bevacizumab use

Grey Horizon, 26 Nov 2024

Final analysis of the Keynote-826 phase III trial, has shown that adding pembrolizumab to chemotherapy has increased progression…

This page shows the most recent blog posts that mention this research output. Click here to find out how to access more activity.